Inhibition of Advanced Glycation End Products. An Implicit Goal in Clinical Medicine for the Treatment of Diabetic Nephropathy?

@article{citeulike:2712266, abstract = {Several factors have been incriminated in the genesis of diabetic nephropathy. To elucidate their interplay, we have used a hypertensive, obese, diabetic rat model with nephropathy (SHR/NDmcr-cp) that mimics human type 2 diabetes. This model is characterized by hypertension, obesity with the metabolic syndrome, diabetes with insulin resistance, and intrarenal advanced glycation end product (AGE) accumulation. In order to achieve renoprotection, which was evaluated by histology and albuminuria, various therapeutic approaches were used: caloric restriction, antihypertensive agents (angiotensin II receptor blocker [ARB] and calcium channel blocker), lipid- (bezafibrate) or glucose-lowering (insulin and pioglitazone) agents, and cobalt chloride (a hypoxia-inducible factor activator). Altogether, renoprotection is not necessarily associated with blood pressure or glycemic control. By contrast, it is almost always associated with decreased AGE formation, with the exception of insulin, which induces hyperinsulinemia, eventually leading to an overproduction of transforming growth factor-beta. AGE formation is reduced directly by in vitro active compounds (e.g., ARBs) or indirectly by in vitro inactive compounds (e.g., pioglitazone and cobalt). In the latter cases, AGE reduction may reflect a decreased oxidative stress as it is concomitant with a marked reduction of oxidative stress markers. It remains to be seen whether the renoprotection offered by these various approaches may be additive.}, author = {Miyata, Toshio and Izuhara, Yuko }, citeulike-article-id = {2712266}, doi = {10.1196/annals.1433.019}, journal = {Annals of the New York Academy of Sciences}, keywords = {age, dn}, number = {1}, pages = {141--146}, posted-at = {2008-04-24 09:39:38}, priority = {2}, title = {Inhibition of Advanced Glycation End Products. An Implicit Goal in Clinical Medicine for the Treatment of Diabetic Nephropathy?}, url = {http://www.blackwell-synergy.com/doi/abs/10.1196/annals.1433.019}, volume = {1126}, year = {2008} }

TY - JOUR ID - citeulike:2712266 L3 - citeulike-article-id:2712266 TI - Inhibition of Advanced Glycation End Products. An Implicit Goal in Clinical Medicine for the Treatment of Diabetic Nephropathy? JF - Annals of the New York Academy of Sciences VL - 1126 IS - 1 SP - 141 EP - 146 N2 - Several factors have been incriminated in the genesis of diabetic nephropathy. To elucidate their interplay, we have used a hypertensive, obese, diabetic rat model with nephropathy (SHR/NDmcr-cp) that mimics human type 2 diabetes. This model is characterized by hypertension, obesity with the metabolic syndrome, diabetes with insulin resistance, and intrarenal advanced glycation end product (AGE) accumulation. In order to achieve renoprotection, which was evaluated by histology and albuminuria, various therapeutic approaches were used: caloric restriction, antihypertensive agents (angiotensin II receptor blocker [ARB] and calcium channel blocker), lipid- (bezafibrate) or glucose-lowering (insulin and pioglitazone) agents, and cobalt chloride (a hypoxia-inducible factor activator). Altogether, renoprotection is not necessarily associated with blood pressure or glycemic control. By contrast, it is almost always associated with decreased AGE formation, with the exception of insulin, which induces hyperinsulinemia, eventually leading to an overproduction of transforming growth factor-beta. AGE formation is reduced directly by in vitro active compounds (e.g., ARBs) or indirectly by in vitro inactive compounds (e.g., pioglitazone and cobalt). In the latter cases, AGE reduction may reflect a decreased oxidative stress as it is concomitant with a marked reduction of oxidative stress markers. It remains to be seen whether the renoprotection offered by these various approaches may be additive. KW - age KW - dn AU - Miyata, Toshio AU - Izuhara, Yuko PY - 2008/// UR - http://www.blackwell-synergy.com/doi/abs/10.1196/annals.1433.019 ER -